<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383200</url>
  </required_header>
  <id_info>
    <org_study_id>20101016</org_study_id>
    <nct_id>NCT01383200</nct_id>
  </id_info>
  <brief_title>Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK</brief_title>
  <official_title>Comparison of 0.5% Tetracaine Drops Versus 2% Lidocaine Gel for Anesthetic Efficacy and Comfort in Patients Undergoing LASIK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will be comparing two different types of anesthetic, a
      numbing eye drop and a numbing gel, to test if they are equally effective or if one has a
      better outcome in terms of the level of comfort you experience one hour and one day after
      your surgery. The two medications are commonly used and appear to be equally effective for
      other types of eye surgery, such as cataract surgery. This study will show if one type of
      anesthesia is preferred over another by patients getting LASIK. Before your LASIK procedure,
      you will be given a short questionnaire to determine the baseline comfort of your eyes. In
      the operating room, one type of anesthetic will be put in one eye, and the other medication
      will be put in the other eye. Which anesthetic you get in each eye will be chosen in a random
      way (similar to flipping a coin). After your LASIK surgery, the investigators will ask you if
      you felt more comfort in your right eye, your left eye, or if they were equal, and the
      investigators will ask you the same survey questions that were asked prior to your LASIK to
      get more details about your experience.

      *Of note- the randomization being done is for which eye will be receiving the lidocaine and
      which eye will be receiving the tetracaine. Each patient will receive lidocaine in 1 eye and
      tetracaine in the other eye, the randomization is for each individual eye. This means, of 11
      patients in our study, 22 eyes received treatment. 11 eyes received lidocaine and 11 eyes
      received tetracaine.

      when we did our comparison, 11 values were used for lidocaine and 11 eyes were used for
      tetracaine, giving a total of 22 eyes. This is important to note since the randomization
      refers to EYE for each individual patient, and not for the patient (ie: participant means 1
      eye, not 1 person in the descriptions below).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome measures involve comparing the right eye and left eye for severity of 12 different
      symptoms, that are recorded in severity on a 1-5 scale. A score of 1 means no symptoms and 5
      means severe. The 12 measurements include sharp pain, dull ache, pain during movement,
      stinging sensation, itching, light sensitivity, watery eyes, dry eyes, sandy sensation,
      pressure sensation, decreased vision, and blurry vision.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    eyes that received gel had slightly thinner than intended flaps
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Score on Pain Scale</measure>
    <time_frame>1 hour (60minutes) post LASIK operation</time_frame>
    <description>Do you have sharp pain in your eye? Pain will be assessed by units on a scale of 1-5: 1 means no symptoms, 2 means slight discomfort, 3 means mild discomfort, 4 means moderate discomfort, and 5 means severe discomfort</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Tetracaine R/Lidocaine L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracaine L/Lidocaine R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracaine drop</intervention_name>
    <description>0.5% Tetracaine Right eye / 2% Lidocaine Left eye</description>
    <arm_group_label>Tetracaine R/Lidocaine L</arm_group_label>
    <arm_group_label>Tetracaine L/Lidocaine R</arm_group_label>
    <other_name>TetraVisc, Altacaine, AK-T-Caine and Pontocaine Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine gel</intervention_name>
    <description>0.5% Tetracaine Left eye / 2% Lidocaine Right eye</description>
    <arm_group_label>Tetracaine R/Lidocaine L</arm_group_label>
    <arm_group_label>Tetracaine L/Lidocaine R</arm_group_label>
    <other_name>Akten</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers of age 18 years or greater

        Exclusion Criteria:

          -  Previous reaction/allergy to the same drug class

          -  prior ocular surgery

          -  active facial injuries

          -  any active current ophthalmological disease

          -  history of diabetes

          -  any current non- Over The Counter pain medication

          -  inability to complete the questionnaire.

          -  Economically or educationally disadvantaged persons, Prisoners, or Children

          -  Patients with fluctuating or impaired decision-making capacity

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SONIA YOO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>January 14, 2013</results_first_submitted>
  <results_first_submitted_qc>March 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Sonia Yoo</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>comfort</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period is now over. Eligible patients included healthy patients undergoing bilateral LASIK surgery.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tetracaine Right Eye / Lidocaine Left Eye</title>
          <description>Each eye of the Subject was randomized using random number tables to receive either topical 0.5% tetracaine drops or 20% lidocaine gel
11 eyes received 0.5% tetracaine drops.</description>
        </group>
        <group group_id="P2">
          <title>Tetracaine Left Eye / Lidocaine Right Eye</title>
          <description>Each eye of the Subject was randomized using random number tables to receive either topical 0.5% tetracaine drops or 20% lidocaine gel
11 eyes received 20% lidocaine gel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TetracaineRight Eye / LidocaineLeft Eye</title>
          <description>0.5% tetracaine drops Right eye /2% lidocaine gel Left eye</description>
        </group>
        <group group_id="B2">
          <title>TetracaineLeft Eye /LidocaineRight Eye</title>
          <description>0.5% tetracaine drops Left eye / 2% lidocaine gel Right eye</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Score on Pain Scale</title>
        <description>Do you have sharp pain in your eye? Pain will be assessed by units on a scale of 1-5: 1 means no symptoms, 2 means slight discomfort, 3 means mild discomfort, 4 means moderate discomfort, and 5 means severe discomfort</description>
        <time_frame>1 hour (60minutes) post LASIK operation</time_frame>
        <population>Five participants received tetracaine right eye and lidocaine left eye and six participants received lidocaine right eye and tetracaine left eye. A total of 22 eyes were analyzed for pain.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetracaine</title>
            <description>0.5% tetracaine drops</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine</title>
            <description>2% lidocaine gel</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Score on Pain Scale</title>
          <description>Do you have sharp pain in your eye? Pain will be assessed by units on a scale of 1-5: 1 means no symptoms, 2 means slight discomfort, 3 means mild discomfort, 4 means moderate discomfort, and 5 means severe discomfort</description>
          <population>Five participants received tetracaine right eye and lidocaine left eye and six participants received lidocaine right eye and tetracaine left eye. A total of 22 eyes were analyzed for pain.</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread=".75"/>
                    <measurement group_id="O2" value="2.01" spread=".93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tetracaine Right Eye / Lidocaine Left Eye</title>
          <description>0.5% Tetracaine drops Right eye / 2% Lidocaine Left eye</description>
        </group>
        <group group_id="E2">
          <title>Tetracaine Left Eye / Lidocaine Right Eye</title>
          <description>0.5% Tetracaine Left eye / 2% Lidocaine Right eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonia Yoo</name_or_title>
      <organization>Bascom Palmer Eye Institute</organization>
      <phone>305-243-2020</phone>
      <email>syoo@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

